Terry Dagnon - 20 Apr 2023 Form 4 Insider Report for Outlook Therapeutics, Inc. (OTLK)

Reporting relationship: Chief Operations Officer
Issuer ticker: OTLK
Reported as of: 20 Apr 2023
Net transaction value: -$590,200
SEC form: 4
Accepted by SEC: 21 Apr 2023, 21:05:47 UTC
Prior SEC filing: 19 Apr 2023
Source filing: View source filing
Reporting owner signature: /s/ Lawrence Kenyon, Attorney-in-Fact

Key filing fact

Terry Dagnon filed Form 4 for Outlook Therapeutics, Inc. (OTLK) on 21 Apr 2023.

Key facts

This page summarizes Terry Dagnon's Form 4 filing for Outlook Therapeutics, Inc. (OTLK).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 21 Apr 2023, 21:05.

Change

Previous filing in this sequence was filed on 19 Apr 2023.
Current net transaction value: -$590,200.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OTLK transaction

Common Stock

Sale

Transaction value: $590,200
Shares: -520,000
Change %: -44%
Price: $1.14
Shares after: 653,058
Date: 20 Apr 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

These shares were sold to cover taxes upon lapse of Issuer's repurchase right as to 75% of the shares as provided in that certain Consulting Agreement dated January 27, 2020.